Early data presented by Cassava Sciences demonstrates the safety of their Alzheimer’s drug simufilam, which is currently in Phase 3 clinical trials. But in late…
Cassava Sciences revealed positive clinical data from their simufilam trial, a potentially disease-modifying therapy for treating Alzheimer’s. Their preliminary study showed that simufilam significantly…
Wall Street traders seem to have gained a new favorite potential Alzheimer’s treatment as shares of Cassava Science, a small and virtually unknown company,…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
DEVELOPING STORY, updated 30 October, 2023: In August 2021, the biotechnology company Cassava Sciences — makers of simufilam, an experimental Alzheimer drug currently in…
The media is reporting that recent fraud allegations undermine the leading theory about the cause of Alzheimer’s. But some of the field’s most established…
The biotechnology company Cassava Sciences — makers of simufilam, an anti-Alzheimer’s drug currently in Phase III clinical trials — was accused of scientific misconduct…
Scientists are diversifying their approaches to finding an effective treatment for Alzheimer’s as clinical trials targeting beta-amyloid plaques, one of the hallmarks of the…